Dallas, Texas, United States, March 2025 – Nanoscope Therapeutics Inc., a biotech company dedicated to restoring vision in individuals affected by retinal degenerative diseases, has announced the appointment of Ashish Patel, PhD, as Senior Vice President, Sales and Marketing. Dr. Patel will be responsible for leading Nanoscope’s commercial strategy as the company moves closer to launching its optogenetic therapies.
Dr. Patel is a highly regarded leader in the pharmaceutical and biotech sectors, with a proven track record in both commercial and R&D roles across some of the world’s most recognized organizations. He brings deep expertise in retinal diseases, including sales leadership, brand strategy, and product launches.
“With his unique blend of scientific and commercial expertise, particularly in the treatment of retinal diseases, Dr. Patel is well-equipped to drive Nanoscope’s sales and marketing strategy as we move towards commercialization of our optogenetic therapies,” said Sulagna Bhattacharya, Co-founder and CEO of Nanoscope Therapeutics.
Dr. Patel most recently served as Vice President of Sales at Iveric Bio (now Astellas), where he led the launch of IZERVAY™, a treatment for geographic atrophy. Before that, he led marketing and launch efforts for BEOVU® at Novartis, addressing wet AMD. He also had an extensive tenure at Bayer, holding multiple roles in brand, sales, and research, including serving as the global launch lead for the fastest-growing indication within Bayer’s EYLEA® retina franchise.
He began his career as a senior R&D scientist with Novartis and holds a PhD in physiology and biophysics from Stony Brook University, an MBA from NYU Stern, and a BS in biophysics from USC. He was also a graduate fellow in molecular biology at MIT.
“Nanoscope is at the precipice of being the first to deliver life-changing, mutation-independent therapies to patients with the highest unmet needs in retina,” said Dr. Patel. “I’m excited to join the accomplished team at Nanoscope, and I look forward to helping lead our commercialization and launch preparations as we progress in our mission to help the millions of patients worldwide impaired by retinal degenerative diseases for which no treatment currently exists.”
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is pioneering mutation-agnostic optogenetic gene therapies designed to restore sight in patients affected by retinal degenerative diseases for which no treatments currently exist. The company’s lead candidate, MCO-010, is being evaluated in retinitis pigmentosa (RP) and Stargardt disease, both of which have received FDA Fast Track and Orphan Drug designations. With a pipeline that includes non-viral and AAV-based delivery platforms, Nanoscope is positioned at the forefront of ocular gene therapy innovation.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
